Safety and efficacy profile of cyclin ‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

ConclusionsHematologic adverse events were common in palbociclib ‐treated cancer patients. Since palbociclib produced a higher PFS rate with a low serious complication rate, it can be a promising novel target therapy drug for treating ER‐positive and HER2‐negative breast cancer.

Source: Cancer Medicine - March 20, 2019 Category: Cancer & Oncology Authors: Linghong Guo, Yuanyuan Hu, Xi Chen, Qingfang Li, Benling Wei, Xuelei Ma Tags: ORIGINAL RESEARCH Source Type: research